First-Choice Insulin When Starting Insulin Therapy
Basal insulin is the first-choice insulin when initiating insulin therapy, with long-acting basal insulin analogs (insulin glargine or insulin degludec) preferred over NPH insulin due to lower hypoglycemia risk and once-daily dosing convenience. 122
Recommended Starting Regimen
For Type 2 Diabetes (Insulin-Naïve Patients)
Start with basal insulin alone using one of these options:
- Insulin glargine (100 U/mL or 300 U/mL): Start at 10 units once daily OR 0.1-0.2 units/kg/day 122
- NPH insulin: Start at 10 units at bedtime OR 0.1-0.2 units/kg/day 1
- Insulin degludec or detemir: Start at 10 units once daily OR 0.1-0.2 units/kg/day 3
The 2025 ADA Standards of Care explicitly recommend starting with basal insulin as the first injectable therapy when initiating insulin 1. The FDA-approved dosing for insulin glargine confirms 0.2 units/kg or up to 10 units once daily as the standard starting dose 22.
For Type 1 Diabetes
Basal insulin must be combined with short-acting prandial insulin from the start. Begin with approximately one-third of total daily insulin requirements as basal insulin, with the remainder covered by rapid-acting insulin at meals 22.
Why Basal Insulin First?
The algorithmic approach prioritizes basal insulin because:
- Targets fasting hyperglycemia first - the foundation of glycemic control
- Simple once-daily dosing improves adherence
- Lower hypoglycemia risk compared to premixed or prandial-only regimens
- Easier titration with clear fasting glucose targets
Choosing Between Basal Insulin Options
Second-generation basal analogs (glargine 300 U/mL, degludec) offer advantages over first-generation options:
- Less hypoglycemia (especially nocturnal) 45
- Longer duration of action (>24 hours) 65
- Greater flexibility in administration timing 6
- Lower intra-patient variability 6
However, NPH insulin remains acceptable when cost is prohibitive or in resource-limited settings 1. The 2025 ADA guidelines include NPH as a viable option with specific conversion guidance when switching to analogs 1.
Titration Protocol
Use an evidence-based titration algorithm:
- Set individualized fasting plasma glucose (FPG) goal (typically 80-130 mg/dL)
- Increase by 2 units every 3 days until FPG goal achieved without hypoglycemia 1
- For NPH/detemir/glargine 100: Can increase by 1 unit daily 3
- For glargine 300/degludec: Can increase by 2-4 units once or twice weekly 3
If hypoglycemia occurs: Determine cause; if no clear reason, reduce dose by 10-20% 1
When NOT to Start with Basal Insulin Alone
Consider insulin as first injectable but use different approach when:
- Symptoms of severe hyperglycemia present
- A1C >10% (>86 mmol/mol) or glucose ≥300 mg/dL (≥16.7 mmol/L) - may need more aggressive regimen 1
- Type 1 diabetes suspected - requires basal-bolus from start 12
In these situations, you may need to initiate with higher doses or add prandial insulin immediately.
Common Pitfalls to Avoid
Clinical inertia is the biggest barrier - don't delay insulin initiation when oral agents fail to achieve target A1C 7. The evidence shows early insulin initiation prevents long-term complications.
Overbasalization - continuing to escalate basal insulin dose beyond approximately 0.5-1.0 units/kg/day without meaningful FPG reduction 3. When this occurs, add prandial insulin or GLP-1 RA rather than further increasing basal dose 1.
Inadequate titration - many patients remain on starting doses. Titrate aggressively to FPG goal using the structured algorithms above 13.